Alps Advisors Inc
- SEC CIK
- 0001376113
- Latest filing
- Jul 29, 2026
BTAIQ holding history
BioXcel Therapeutics, Inc. in every 13F filed by Alps Advisors Inc, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
BTAIQ overviewAll 13F holders of BTAIQFull Q2 2026 holdings
- Shares (Q2 2023)
- 0
- Sold out in Q2 2023
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 9
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2023 | 0 | $0 | 0.0% | −18,458−100.0% | Sold out | Holders |
| Q1 2023 | 18,458 | $344.4K | <0.1% | −536−2.8% | Reduced | Holders |
| Q4 2022 | 18,994 | $408.0K | <0.1% | +3,748+24.6% | Added | Holders |
| Q3 2022 | 15,246 | $180.0K | <0.1% | −1,350−8.1% | Reduced | Holders |
| Q2 2022 | 16,596 | $219.0K | <0.1% | −12,158−42.3% | Reduced | Holders |
| Q1 2022 | 28,754 | $601.0K | <0.1% | −3,621−11.2% | Reduced | Holders |
| Q4 2021 | 32,375 | $658.0K | <0.1% | −1,903−5.6% | Reduced | Holders |
| Q3 2021 | 34,278 | $1.04M | <0.1% | +1,840+5.7% | Added | Holders |
| Q2 2021 | 32,438 | $943.0K | <0.1% | −11,642−26.4% | Reduced | Holders |
| Q1 2021 | 44,080 | $1.90M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.